Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Drops By 91.3%

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 43,229 shares, a drop of 91.3% from the December 15th total of 494,378 shares. Based on an average daily volume of 1,635,913 shares, the days-to-cover ratio is currently 0.0 days. Approximately 7.0% of the shares of the company are short sold. Approximately 7.0% of the shares of the company are short sold. Based on an average daily volume of 1,635,913 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

BDRX has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Biodexa Pharmaceuticals to a “sell” rating in a research report on Saturday, December 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Biodexa Pharmaceuticals presently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Price Performance

NASDAQ:BDRX traded down $0.05 on Tuesday, reaching $2.28. The stock had a trading volume of 90,312 shares, compared to its average volume of 102,494. Biodexa Pharmaceuticals has a 1-year low of $2.22 and a 1-year high of $92.00. The stock has a fifty day moving average price of $4.26 and a 200-day moving average price of $6.21.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.